All In Biotech

Drug Trial Radar · NCT05369286

A Study to Evaluate the Safety and Efficacy of Max-40279 and Toripalimab in Patients With Advanced Solid Tumors

A Phase 1 Study to Evaluate the Safety and Efficacy of Max-40279-01 in Combination With Toripalimab in Patients With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: May 11, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

28

Planned (sponsor's estimate)

Start

Apr 11, 2022

Primary completion

May 31, 2023

Study completion Aug 31, 2023

Sponsor

Lead sponsor
Maxinovel Pty., Ltd.Industry
Sponsor type
Industry
First posted
May 11, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This include two parts, part 1 is a dose escalation study and part 2 is a dose expansion study.

Conditions

  • Solid Tumor

Interventions

  • "MAX-40279-01" and "Toripalimab"Drug

    "MAX-40279-01"combined with "Toripalimab"

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. DLTsTime frame: 21 days
  2. Incidence of Treatment-Emergent Adverse EventsTime frame: 24 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Institute of The Sixth Affiliated Hospital Sun Yat-sen University

    Guangzhou, Guangdong, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.